News

Cellzome secures second alliance with GSK

Wednesday 10 March 2010

Cellzome Inc said that it has secured a new drug discovery deal with GlaxoSmithKline under which the companies will seek to identify small-molecule drugs against epigenetic targets. Cellzome will receive €33 million upfront.

Country: United Kingdom

Read more

Novartis plans $5 billion, three-tranche bond issue

Wednesday 10 March 2010

Novartis AG is raising $5 billion with a three-tranche bond issue to finance part of its pending acquisition of Alcon Inc, a large eye-care company with sales of approximately $6.5 billion in 2009.

Country: Switzerland

Read more

Therapeutic vaccine producer raises €13.1 million

Tuesday 9 March 2010

A French producer of therapeutic vaccines for cancer has raised €13.1 million from private and public sources in order to bring its lead product, a therapeutic human papillomavirus vaccine, into the clinic.

Country: France

Read more

Actelion receives FDA complete response letter for Zavesca

Tuesday 9 March 2010

Actelion Ltd said that it has received a complete response letter from the US Food and Drug Administration for its treatment for Niemann-Pick disease, Zavesca (miglustat). This means the agency cannot approve the application in its present form.

Country: Switzerland

Read more

Ark Therapeutics drops Cerepro appeal

Tuesday 9 March 2010

Ark Therapeutics Group Plc has dropped its appeal against a negative opinion from the European Medicines Agency for its gene therapy for brain cancer, Cerepro. It also announced that it is in talks about a possible takeover of the company. Ark disclosed the developments on 9 March 2010.

Country: United Kingdom

Read more

Zalutumumab fails to meet primary endpoint of overall survival

Tuesday 9 March 2010

Genmab A/S said that its antibody for head and neck cancer, zalutumumab, has failed to show overall survival in a Phase 3 study in which the drug was being tested in combination with best supportive care versus best standard care alone.

Country: Denmark

Read more

Recentin fails to meet primary endpoint in cancer trial

Monday 8 March 2010

AstraZeneca Plc said that its candidate drug, Recentin (cediranib), for patients with first-line metastatic colorectal cancer, failed to meet its primary endpoint of non-inferiority in progression-free survival in a Phase 2/3 trial.

 

Country: United Kingdom

Read more

Roche and Biogen Idec suspend RA trials with ocrelizumab

Monday 8 March 2010

The Roche Group and Biogen Idec of the US have suspended clinical trials of the humanized anti-CD20 monoclonal antibody, ocrelizumab, in four rheumatoid arthritis trials because of safety issues. The drug was in Phase 2 and 3 trials.

 

Country: Switzerland

Read more

Key milestones for BioAlliance in the second quarter

Friday 5 March 2010

BioAlliance Pharma SA is looking ahead to three possibly transforming events in the second quarter of 2010 that could secure its standing as a recognised specialty pharmaceutical company in Europe.

Country: France

Read more

Alzheimer’s drug fails at Phase 3

Thursday 4 March 2010

An investigational drug for patients with Alzheimer’s disease, Dimebon (latrepirdine), has failed in a Phase 3 trial because it could not show statistically significant improvements in patients compared with placebo for cognition and global function.

Country: United States

Read more